Pentoxifylline has several actions that improve blood rheology and tissue perfusion and may therefore potentially be applicable to diabetic neuropathy. The aims of this study were to ascertain whether 2 weeks of treatment with pentoxifylline could correct nerve conduction velocity and blood flow deficits in 6-week streptozotocin-diabetic rats and to examine whether the effects were blocked by co-treatment with the cyclooxygenase inhibitor, flurbiprofen, or the nitric oxide synthase inhibitor, NG-nitro-L-argi nine. Diabetic deficits in sciatic motor and saphenous sensory nerve conduction velocity were 56.5% and 69.8% corrected, respectively, with pentoxifylline treatment. Sciatic endoneurial blood flow was approximately halved by diabetes and this deficit was 50.4% corrected by pentoxifylline. Flurbiprofen co-treatment markedly attenuated these actions of pentoxifylline on nerve conduction and blood flow whereas G N-nitro-L-arginine was without effect. Thus, pentoxifylline treatment confers neurovascular ben.efits in experimental diabetic neuropathy, which are linked at least in part to cyclooxygenasemediated metabolism.
INTRODUCTION
The early neuropathic changes in experimental diabetes, such as diminished conduction velocity (NCV), are believed to be largely attributable to a reduction in nerve perfusion (Tuck et al., 1984; Cameron et al., 1991) . Parallels may be drawn with reduced sural nerve blood flow and the presence of endoneurial hypoxia in neuropathic patients (Tesfaye et al., 1994) .
Several vasodilators have been identified that partially prevent or correct nerve dysfunction in diabetic rats , and patients (Tesfaye et al., 1994) , presumably by improving perfusion and oxygenation. Major contributions to impaired nerve blood flow are made by decreased vasa nervorum prostacyclin and nitric oxide (NO) production or action, and elevated vasoconstrictor activity (Ward et al., 1989 ; 1995 Cameron and Cotter, 1996a) . In turn, these changes result from metabolic consequences of hyperglycemia, including increased polyol pathway, elevated production of reactive oxygen species, advanced glycation and protein kinase C activation Cameron and Cotter, 1996b; Sima and Sugimoto, 1999) .
Diabetes also causes elevated blood viscosity, decreased red cell deformability, increased platelet activation, a prothrombotic state, and phagocyte activation that may contribute to reduced nerve perfusion (Simpson, 1988; Ceriello, 1993) .
Pentoxifylline is a methylxanthine derivative possessing hemorheological actions that improve the microcirculation (Ward and Clissold, 1987) . It is a phosphodiesterase inhibitor that can cause vasodilation in some vessels by endothelium-dependent and independent mechanisms (Hansen, 1994; Kaputlu and Sadan, 1994) . Pentoxifylline also inhibits production of platelet activating factor, reduces platelet aggregation, increases red cell membrane fluidity, and reduces the production of inflammatory cytokines, particularly tumor necrosis factor, by phagocytes and vascular endothelium (Adams et al., 1995; Ambrus et al., 1995; Bernard et al., 1995; Mandell, 1995) . Thus, pentoxifylline has vascular and rheological actions that may counteract some of the changes in diabetes that contribute to nerve dysfunction. The aim of this study was to determine whether pentoxifylline treatment corrects NCV and perfusion deficits in diabetic rats. As some putative actions of pentoxifylline involve correction or potentiation of the effects of prostacyclin and NO systems, the outcomes of co-treatment with the cyclooxygenase inhibitor, flurbiprofen, or the NO synthase inhibitor, N-nitro-L-arginine, were examined to further elucidate underlying mechanisms. Preliminary data were presented at a meeting of the International Diabetes Federation . Separate groups of rats were used to assess motor and sensory NCV (n 10-16), and sciatic nerve perfusion (n 9-10).
At the end of the treatment period, rats were anesthetized with urethane (Sigma; 1-1.5mg kg-1), or for the nerve perfusion experiments with thiobutabarbital (Zeneca; 50-100 mg kg-1), by intraperitoneal injection. The trachea was cannulated for artificial ventilation. A carotid cannula was used to monitor mean systemic blood pressure in rats undergoing blood flow measurement. Motor NCV was assessed between the sciatic notch and the knee in the nerve branch innervating the tibialis anterior muscle as previously described (Cameron et al., 1989) . This is representative of the whole sciatic nerve in terms of susceptibility to diabetes and treatment effects. Sensory NCV was measured in saphenous nerve between the groin and the ankle as previously described (Cameron et al., 1989) . Rectal and nerve temperatures were monitored, and kept between 36.5 and 37.5C.
Sciatic endoneurial blood flow was measured by microelectrode polarography and hydrogen clearance as previously described (Cameron et al., 1991) . Briefly, the core temperature of the rat was monitored and kept between 37 and 38C, using a rectal probe and radiant heat. The skin around the sciatic nerve incision was sutured to a metal ring and used to form a pool, which was filled with mineral oil. Pool temperature was maintained between 35 and 37C by radiant heat during blood flow measurements. Rats were given neuromuscular blockade using d-tubocurarine (Sigma, 2mg kg -1 via the carotid cannula) and we.re artificially ventilated.
The level of anesthesia was monitored by observing blood pressure reactions to manipulations and supplementary anaesthetic was given as necessary. A glass-insulated platinum microelectrode was inserted into the middle portion of the sciatic .nerve, above its trifurcation, and polarized at 0.25 V with respect to a subcutaneous reference electrode. 10% H2 was added to the inspired gas, the proportions of 02 and N2 being adjusted to 20% and 70% respectively.
When the H2 current recorded by the electrode had stabilized, indicating equilibrium with arterial blood, the H2 supply was shut off and N2 delivery was increased appropriately. The H2 clearance curve was recorded until baseline values were reached, the latter being defined as no systematic decline in electrode current over 5min. This procedure was then repeated at another site of the sciatic nerve. After the experiment, clearance curves were digitized and mono-exponential or bi-exponential curves were fitted to the data by computer using non-linear regression software that employs the Marquardt algorithm and the least squares method for optimizing goodness-of-fit (Prism, Graphpad, San Diego, CA, USA). The slow exponent was taken to reflect nutritive (capillary) flow (Day et al., 1989 non-diabetic group (P<0.001). Co-treatment with N-nitro-L-arginine did not significantly alter the effect of pentoxifylline (55.44-4 .6% correction; P <0.001 versus diabetic and nondiabetic groups). In contrast, flurbiprofen attenuated pentoxifylline's action by 52.94-12.6% (P < 0.01), although the resultant motor NCV value remained significantly (P < 0.05) greater than that of the diabetic control group. Sensory saphenous NCV (Fig. 1B) was 12.1 4-1.9% (P < 0.001) reduced by untreated diabetes. This was completely corrected by pentoxifylline treatment (P <0.01). N-nitro-L-arginine co-treatment was without effect on pentoxifylline's action; NCV was in the non-diabetic range. However, with flurbiprofen co-treatment, NCV remained at the untreated diabetic level (P < 0.01 versus pentoxifylline treatment alone).
A 48.44-2.2% diabetic deficit (P<0.001) in sciatic nutritive endoneurial blood flow ( Fig. 2A) was partially (44.7 4-8.4%; P <0.001) corrected by pentoxifylline treatment, although a significant deficit remained compared to the nondiabetic control group (P <0.001). The effect of pentoxifylline was not significantly attenuated by N -nitro-L-arginine co-treatment, but it was 84.0 4-4.0% diminished (P < 0.05) by flurbiprofen such that the resultant value was in the upper diabetic range.
Mean systemic blood pressure ( Day et al., 1989) . The weighted sum of these components describes total or composite endoneurial flow (Fig. 3A) . This was 58.3 4-3.3% (P < 0.001) reduced by diabetes and 55.6 4-14.0% (P < 0.01) corrected by pentoxifylline treatment, the resultant value being not significantly different from that of the non-diabetic control group.
Both NG-nitro-L-arginine (P < 0.01) and flurbiprofen (P <0.001) co-treatments completely attenuated the effects of pentoxifylline on composite endoneurial blood flow. Similar effects were seen for composite vascular conductance (Fig.  3B) , the value for pentoxifylline treatment alone being in the non-diabetic range whereas those for NG-nitro-L-arginine and flurbiprofen co-treatment were in the diabetic range. The percentage of hydrogen clearance carried by nutritive flow (Fig. 3C) was not significantly affected by diabetes. However, with pentoxifylline treatment alone, this was approximately halved compared to all the other groups (P < 0.05). DISCUSSION appreciable pressure autoregulation (Day et al., 1989) flow results are expressed as vascular conductance (Fig. 2C) to several unrelated treatments, including aldose reductase inhibitors, a vasodilator and an antioxidant, has been previously observed in diabetic rats (Cameron et al,, , 1989 (Cameron et al,, , 1994c Nagamatsu et al., 1995 for caudal nerve in diabetic rats . That degree of protection is in reasonable agreement with the magnitude of correction of proximal sciatic nerve motor NCV seen with pentoxifylline treatment in this study. (Bernard et al., 1995; Mandell, 1995) . The latter can evoke several deleterious vascular changes in diabetes relevant to vasa nervorum dysfunction. Tumor necrosis factor can activate protein kinase C (Deisher et al., 1993) and stimulate nuclear factor B in endothelial cells (Tozawa et al., 1995) . This transcription factor causes several effects including elevated endothelin-1 synthesis, decreased NO production, and altered expression of adhesion molecules and increased cell-endothelium interaction (Collins, 1993; Rubanyi and Polokoff, 1994; Limb et al., 1996; Bierhaus et al., 1997) . Circulating levels of tumor necrosis factor are elevated in diabetic rats, and this may be prevented by treatment with N-acetyl-L-cysteine, which also restores endothelial function, endoneurial blood flow and NCV (Archibald et al., 1996; Love et al., 1996a; Sagara et al., 1996) .
Pentoxifylline has also been identified as a scavenger of hydroxyl (but not superoxide) radicals in vitro (Freitas and Filipe, 1995) over a concentration range relevant to the dose used in this in vivo study. The production of reactive oxygen species is increased by diabetes and endogenous antioxidant defense mechanisms in nerve are compromised Nagamatsu et al., 1995; Nickander et al., 1994) . Hydroxyl radicals are short-lived but highly reactive and can be formed by transition metal catalyzed processes such as the Fenton reaction, which are relevant to diabetes (Cameron and Cotter, 1995a) . Another source of hydroxyl radicals is the breakdown of peroxynitrite (Beckman et al., 1990) , formed from the reaction between NO and superoxide. This process probably contributes to endothelial dysfunction (Pieper et al., 1993) and neurovascular deficits Maxfield et al., 1997) in experimental diabetes. While there have not been any reports on the effects of specific hydroxyl radical scavengers on nerve function, transition metal chelators are effective in restoring nerve blood flow, NCV and regenerative capacity in experimental models of diabetic neuropathy (Cameron and Cotter, 1995a; Love et al., 1996b) .
The platelet anti-aggregatory effect of pentoxifylline is likely to depend on inhibition of platelet phosphodiesterase, allowing elevated cAMP levels to inhibit the formation of thromboxane A2 (Ward and Clissold, 1987) . However, this requires relatively high doses that may not have been attained in this in vivo experiment. In addition, use of specific thromboxane A2 receptor/thromboxane synthase antagonist treatment only has a modest effect ( 16% correction) on motor NCV in diabetic rats (Dines et al., 1996) . Although the rheological/anti-platelet actions of pentoxifylline may be contributory; alone they are probably not sufficient to account for the effects on neurovascular function in diabetic rats. The improvements in NCV and blood flow with pentoxifylline were attenuated by co-treatment with the cyclooxygenase inhibitor, flurbiprofen, but not by NO synthase inhibition. This suggests that the major action of pentoxifylline in these experiments depended upon cyclooxygenase products rather than NO. A vasa nervorum prostacyclin deficit contributes to reduced nerve blood flow in diabetic rats (Ward et al., 1989 ). This appears to be caused primarily by a deficit in substrate availability, since it is corrected by treatment with 0;-6 essential fatty acids such as -y-linolenic or arachidonic acid Hotta et al., 1996) .
The resistance of pentoxifylline treatment to NO synthase inhibition sets it apart from several other drugs that improve endoneurial perfusion and NCV in diabetic rats. These include aldose reductase inhibitors Stevens et al., 1994) , aminoguanidine , antioxidants (Cameron and Cotter, 1995b) and protein kinase C inhibitors . These drugs all attenuate the development of defective NO-mediated endothelium-dependent vasorelaxation in diabetes Archibald et al., 1996) . However, the effects of aldose reductase inhibitors are also opposed by flurbiprofen, perhaps because they moderately improve endothelial production of prostacyclin and other prostanoids and act on the NO system (Law and King, 1990; Wakasugi et al., 1991 . Conversely, flurbiprofen treatment of diabetic rats had the opposite effect, reducing non-nutritive more than the nutritive flow . On the other hand, aldose reductase inhibitors favor nutritive perfusion , although they can increase prostanoid production. It is possible that the different drug effects on endoneurial blood flow depends on how they alter the balance between prostanoid and NO actions on vasa nervorum.
In conclusion, pentoxifylline partially corrected the endoneurial blood flow deficit, and improved NCV in diabetic rats. These neurovascular effects probably depend in large part on a potentiation of prostanoid-mediated vasodilator and rheological actions. Pentoxifylline is used in the treatment of peripheral vascular disease (Ward and Clissold, 1987) , and it is possible that it may also prove useful in the treatment of diabetic neuropathy.
